Stock Price & Analysis

The S1 support level for ACET Stock is $0.86 ,The R1 resistant level for ACET Stock is $1.04.

As of the end of day on 2025-01-23, the price of ACET Stock was $0.918.

The target price for ACET Stock according to analyst rating is 7.00, with the highest price target at 7.00 and the lowest at 7.00. Analysts have a Moderate Buy rating on ACET Stock overall.

The market cap of ACET is $75.6M.

Adicet Bio, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing allogeneic gamma delta T cell therapies for cancer. The Company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. Its product candidate, ADI-001, is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20 used for the treatment of relapsed or refractory B-cell non-Hodgkins lymphoma (NHL). Its pipeline also includes ADI-925, which is a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Its pipeline also includes additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

ACET has a total of 143 employees.